Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SARS-CoV-2 (COVID-19) Severe Pneumonia Clear all
Completed Phase 2 Interventional Results available

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

NCT04481685
View directory record Official record
Conditions
Covid19
Interventions
ATI-450, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 14, 2026, 11:19 AM EDT
Recruiting Phase 3 Interventional

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

NCT07743580
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Secutrelvir, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
12 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Coral Gables, Florida • Miami, Florida • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 11:19 AM EDT
No Longer Available No phase listed Expanded access

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, SARS-CoV Infection
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 14, 2026, 11:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT04365101
View directory record Official record
Conditions
Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic
Interventions
CYNK-001
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Irvine, California • Morristown, New Jersey • Summit, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782
View directory record Official record
Conditions
COVID-19, Hypoxia
Interventions
L-ascorbic acid
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 14, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

NCT04992273
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Not applicable Interventional

A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion

NCT04720794
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), Corona Virus Infection
Interventions
Lucira COVID-19 All-In-One test kit
Device
Lead sponsor
Lucira Health Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 14, 2026, 11:19 AM EDT
Recruiting No phase listed Observational

Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence

NCT04448145
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS-CoV 2
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
7 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 11:19 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472
View directory record Official record
Conditions
Covid-19
Interventions
Convalescent plasma transfusion
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 14, 2026, 11:19 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

NCT07093580
View directory record Official record
Conditions
Healthy Participants
Interventions
S-892216-LAI, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 11:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Saliva as Source of Detection for SARS-CoV-2

NCT04424446
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 14, 2026, 11:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Beaumont Health Large-scale Automated Serologic Testing for COVID-19

NCT04349202
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
EUROIMMUN assay
Diagnostic Test
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
20,614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 14, 2026, 11:19 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

NCT04358081
View directory record Official record
Conditions
Covid-19
Interventions
HCQ, HCQ+AZT, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 14, 2026, 11:19 AM EDT
Completed No phase listed Observational

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

NCT04588363
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
Interventions
SARS-CoV-2 and/or MIS-C Exposure
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 14, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 and Anti-CD14 Treatment Trial

NCT04391309
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
anti-CD14, Placebo, remdesivir
Biological · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Sarasota, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 14, 2026, 11:19 AM EDT
Terminated No phase listed Observational

Serology to COVID-19 for Recording Exposures and Evaluating Needs

NCT04566965
View directory record Official record
Conditions
Covid19, Coronavirus, SARS-CoV Infection
Interventions
SARS-CoV-2
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
232 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

NCT07069309
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
774 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
19
States / cities
Walnut Creek, California • Milford, Connecticut • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

NCT04590547
View directory record Official record
Conditions
Pneumonitis, SARS-CoV Infection
Interventions
GLS-1027, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 14, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
INOpulse, Placebo
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 14, 2026, 11:19 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota

NCT04473183
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, SARS-CoV-2, Corona Virus Infection
Interventions
Specimen Collection, Surveys
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 14, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

NCT05870839
View directory record Official record
Conditions
SARS-CoV, SARS-CoV-2
Interventions
VXCO-100
Biological
Lead sponsor
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 14, 2026, 11:19 AM EDT